Innovating Novel Combination Therapies & Maximising Preclinical & Clinical Development to Improve Glioblastoma Targeting & Increase Investment Opportunities to Ultimately Bring Efficacious Therapies to Patients in Need
Accelerating Innovation in Glioblastoma Drug Development!
The glioblastoma treatment landscape is projected to grow significantly by 2034 - driven by increased adoption of standard-of-care therapies and the rise of novel, science-driven approaches. This momentum has been further energized by Merck’s landmark acquisition of Modifi Bio, sparking renewed hope in a field long challenged by limited investment and clinical breakthroughs.
Looking ahead to 2026, sustaining this progress is critical. The 7th Glioblastoma Drug Development Summit is your essential platform to accelerate new treatments and unlock the future of glioblastoma care.
Join us for a definitive 3-day summit featuring groundbreaking content and six deep-dive workshops, where you’ll connect with over 90 leading experts from biotech, pharma, and investment. Together, we’ll explore:
- Innovating novel combination strategies to overcome resistance and improve efficacy
- Building robust preclinical and clinical frameworks to accelerate translation
- Mobilizing investment and collaboration to bring promising therapies to patients faster
- Harnessing AI’s transformative role in glioblastoma research and development
Join leading organizations, including Laminar Pharma, Medicenna, Merck, AstraZeneca, CNS Pharmaceuticals, Imvax, Tactical Therapeutics and many more!
Together, we’ll unlock actionable insights, forge powerful partnerships, and move closer to delivering transformative therapies for one of the most devastating and underserved cancers.
Attending Companies Include
The diverse content that covered everything from funding GBM trials to new technologies/approaches to early clinical solutions. The round tables were a good way to promote discussion.
Chief Business Officer, Global Coalition for Adaptive Research
I was extremely pleased with the way the entire summit was organized. Everything from the line up of the speakers to the networking opportunities was very well planned and executed.
VP, Research & Development, Diakonos Oncology
The summit covered diverse important topics in GBM field, ranging from more basic to clinical and investment. Great opportunities for discussion on key open topics to understand perspective from leaders in their area of focus.
CEO, Medicenna Therapeutics
Explore the Full Event Guide
- 90+ industry attendees
- 25+ World Class Speaker
- 6 deep-dive workshops, covering end-to-end drug development
- 8+ Hours on Networking
- The world’s only industry-led forum focussed on Glioblastoma drug development
Investor & Partnership Panel:
Despite the urgent unmet need, investment in glioblastoma therapeutics remains constrained by scientific complexity, regulatory uncertainty, and limited commercial upside, making it one of the most underfunded yet high-impact opportunities in neuro-oncology.
In response to this, we have compiled a high-profile group of investors and search and evaluation executives, ready to share their insights, priorities, and advice for biotech looking to secure that all-important funding.
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.